Variability of the Relative Biological Effectiveness of Carbon Ions Among Human Cancer Cell Lines Under Clinically Relevant Irradiation Conditions.

Authors

Kento Tomizawa, Lusi Tania Rahmartani, Ryosuke Kambe, Soichiro Sakamoto, Machi Nakagawa, Shunji Haruna, Makoto Sakai, Atsushi Shibata, Takahiro Oike, Tatsuya Ohno

Published in

Anticancer research. Volume 46. Issue 11. Pages 6063-6073.

Abstract

In Japan, carbon-ion radiotherapy treatment planning uses relative biological effectiveness (RBE) values derived from a single reference cell line. Accumulating evidence indicates that carbon-ion RBE varies among different cancers. However, the magnitude of this variability remains unclear owing to the heterogeneity of the experimental conditions among the studies. This study aimed to elucidate carbon-ion RBE variability across a large panel of human cancer cell lines using clinically relevant irradiation conditions and consistent clonogenic assay methods.
Clonogenic survival in 41 human cancer cell lines after X-ray or carbon-ion irradiation was analyzed. Carbon-ion irradiation was performed at the center of a 6-cm spread-out Bragg peak (290 MeV/nucleon; dose-averaged linear energy transfer, approximately 50 keV/μm). RBE values at doses corresponding to 10% and 50% survival (D₁₀ and D₅₀, respectively) were calculated and compared with population-representative RBE values derived by linear regression and with those of the reference human salivary gland (HSG) cell line.
Population-representative RBE values were 2.09 and 2.28 for D₁₀ and D₅₀, respectively, closely approximating those of HSG cells (1.92 and 2.37). However, approximately 32% of the cell lines exhibited RBE values that deviated by at least 24% from the population-representative values. This variability was greater for D₅₀ than for D₁₀. No association was found between RBE and primary organ or histological subtype.
Substantial inter-cell line RBE variability was observed under consistent and clinically relevant irradiation conditions, indicating that the current fixed-RBE approach contributes to potential overtreatment or undertreatment in a subset of patients.

PMID:
42946417
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.